APA (7th ed.) Citation

Armstrong, A. W., Augustin, M., Beaumont, J. L., Pham, T. P., Hudgens, S., Gordon, K. B., . . . Papp, K. A. (2025). Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials. Dermatology & Therapy, 15(4), 1037. https://doi.org/10.1007/s13555-024-01317-7

Chicago Style (17th ed.) Citation

Armstrong, April W., et al. "Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials." Dermatology & Therapy 15, no. 4 (2025): 1037. https://doi.org/10.1007/s13555-024-01317-7.

MLA (9th ed.) Citation

Armstrong, April W., et al. "Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials." Dermatology & Therapy, vol. 15, no. 4, 2025, p. 1037, https://doi.org/10.1007/s13555-024-01317-7.